Karen Weintraub is a freelance writer based in Boston, Massachusetts.
Karen Weintraub
Freelance Writer
Simons Foundation/Freelance
From this contributor
Technique follows calcium trail to track changes in signaling
Researchers have genetically engineered neurons to fluoresce in response to the calcium signals emitted when they fire, according to a study published 18 October in Neuron.
Technique follows calcium trail to track changes in signaling
By
Karen Weintraub
24 October 2012 | 2 min read
Researchers uncover new drug target for fragile X
Deleting an enzyme that regulates protein synthesis reverses some of the molecular and behavioral deficits in a mouse model of fragile X syndrome, according to research published 2 October in Neuron.
Researchers uncover new drug target for fragile X
By
Karen Weintraub
4 October 2012 | 5 min read
Drug improves social deficits in fragile X syndrome
A drug called arbaclofen improves behavioral problems in people with fragile X syndrome, an inherited condition that can lead to mental retardation and autism, according to the results of a clinical trial published today in Science Translational Medicine. A second study published in the same journal showed that the drug restores normal brain function in a mouse model of the disorder.
Drug improves social deficits in fragile X syndrome
By
Karen Weintraub
19 September 2012 | 5 min read
Explore more from The Transmitter
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
By
Paul Middlebrooks
21 October 2026 | 1 min read
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
By
Claudia López Lloreda
21 October 2026 | 9 min read
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
By
Natalia Mesa
20 October 2026 | 7 min read